Abstract
Jade-1 is originally identified by the yeast two-hybrid system as a protein partner of von Hippel-Lindau (pVHL) tumor suppressor, a well-known renal tumor suppressor. In cellular signaling pathways, many upstream Jade-1 regulators, such as pVHL, CK1α, PC1, and NPHP4, can control its activity by stabilization, phosphorylation, and nuclear translocation. Numerous downstream effectors, including β-catenin, AKT, p21, and Bcl-2, are well modulated by Jade-1, which mainly regulates cell proliferation and apoptosis. Jade-1 is also deemed to be a candidate of transcriptional co-activator associated with histone acetyltransferase (HAT) activity. This review focuses on the anticancer role of Jade-1 in clear cell renal carcinoma and the inhibitory effect of Jade-1 on cystic renal diseases. This review aims to provide a basis of disease prevention or therapy.
Keywords: Jade-1, pVHL, renal cancer, renal cyst, HAT, β-catenin.
Current Molecular Medicine
Title:Jade-1: its structure, regulation and functions in the renal cancer.
Volume: 16 Issue: 1
Author(s): Y.-C. Zhang, W.-Q. Du, R.-Y. Zhang, J.-N. Zheng and D.-S. Pei
Affiliation:
Keywords: Jade-1, pVHL, renal cancer, renal cyst, HAT, β-catenin.
Abstract: Jade-1 is originally identified by the yeast two-hybrid system as a protein partner of von Hippel-Lindau (pVHL) tumor suppressor, a well-known renal tumor suppressor. In cellular signaling pathways, many upstream Jade-1 regulators, such as pVHL, CK1α, PC1, and NPHP4, can control its activity by stabilization, phosphorylation, and nuclear translocation. Numerous downstream effectors, including β-catenin, AKT, p21, and Bcl-2, are well modulated by Jade-1, which mainly regulates cell proliferation and apoptosis. Jade-1 is also deemed to be a candidate of transcriptional co-activator associated with histone acetyltransferase (HAT) activity. This review focuses on the anticancer role of Jade-1 in clear cell renal carcinoma and the inhibitory effect of Jade-1 on cystic renal diseases. This review aims to provide a basis of disease prevention or therapy.
Export Options
About this article
Cite this article as:
Zhang Y.-C., Du W.-Q., Zhang R.-Y., Zheng J.-N. and Pei D.-S., Jade-1: its structure, regulation and functions in the renal cancer., Current Molecular Medicine 2016; 16 (1) . https://dx.doi.org/10.2174/1566524016666151222144511
DOI https://dx.doi.org/10.2174/1566524016666151222144511 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melatonin Induces Apoptosis and Inhibits the Proliferation of Cancer Cells via Reactive Oxygen Species-mediated MAPK and mTOR Pathways
Clinical Cancer Drugs The Current and Future Therapies for Human Osteosarcoma
Current Cancer Therapy Reviews Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression
Current Drug Targets Multi-Nuclear Platinum Drugs: A New Paradigm in Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets Cancer Stem Cells Switch on Tumor Neovascularization
Current Molecular Medicine Platinum-Based Agents for Individualized Cancer Treatment
Current Molecular Medicine Imaging Drug Resistance with Radiolabeled Molecules
Current Pharmaceutical Design Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease
Current Medicinal Chemistry Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells
Current Cancer Drug Targets A Technological Update of Molecular Diagnostics for Infectious Diseases
Infectious Disorders - Drug Targets Role of Preoperative Diagnostic Imaging Procedures in Secondary Hyperparathyroidism
Current Medical Imaging Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors
Current Medicinal Chemistry AG490 Promotes HIF-1α Accumulation by Inhibiting Its Hydroxylation
Current Medicinal Chemistry Finding Relevant Genes Involved in the Cytotoxicity Mechanisms of Anticancer Biophores
Current Computer-Aided Drug Design Current Prodrug Strategies for the Delivery of Nucleotides into Cells
Drug Design Reviews - Online (Discontinued) Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets New-Generation, Non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs
Current Medicinal Chemistry